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Abstract: The heterogeneity of symptoms and disease progression observed in synucleinopathies, of which Parkinson’s 
disease (PD) is the most common representative, poses large problems for the discovery of novel therapeutics. The molecu-
lar basis for pathology is currently unclear, both in familial and in sporadic cases. While the therapeutic effects of L-DOPA 
and dopamine receptor agonists constitute good options for symptomatic treatment in PD, the development of neuroprotective 
and/or neurorestorative treatments for PD and other synucleinopathies faces signiﬁ  cant challenges due to the poor knowledge 
of the putative targets. Recent experimental evidence strongly suggests a central role for neurotoxic α-synuclein oligomeric 
species in neurodegeneration. The events leading to protein oligomerization, as well as the oligomeric species themselves, 
are likely amenable to modulation by small molecules, which are beginning to emerge in high throughput compound screens 
in a variety of model organisms. The therapeutic potential of small molecule modulators of oligomer formation demands 
further exploration and validation in cellular and animal disease models in order to accelerate human drug development.
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Introduction
Protein conformational disorders are a group of diseases associated with the misfolding and aggregation 
of one or more proteins. They are believed to result from the inability of proteins to be functional which, 
in some instances, is associated with the accumulation of abnormally folded proteins. Proteins, as the 42
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main effectors in the cell, play underpinning roles 
in all biological processes. Therefore, it is not 
surprising that the list of these diseases is continu-
ously expanding, as new proteins are identiﬁ  ed and 
their functions understood.
Despite the well-known connection between 
protein misfolding, aggregation, and disease, the 
manner by which misfolding results in disease is 
not clearly understood. In some cases, it seems that 
the deposition of protein aggregates may physically 
disrupt the functioning of speciﬁ  c cell groups and 
the respective tissues and organs where those cells 
are located. In other cases, it seems that the lack 
of functional protein, due to its recruitment into 
the aggregates, results in the failure of crucial cel-
lular processes (Thomas et al. 1995). However, for 
neurodegenerative diseases, such as Alzheimer’s, 
Parkinson’s or the Prion diseases, it appears that 
the symptoms arise from the destruction of cells 
by a “gain of toxic function” that results from the 
aggregation process (via oligomers, protoﬁ  brils, 
amyloid ﬁ  brils or other intermediates) or by a 
combination of both this gain of toxic function and 
a loss of normal function of the protein (Ross and 
Poirier, 2004; Caughey and Lansbury, 2003).
Synucleinopathies
α-synuclein (aSyn), a member of the synuclein 
family of proteins, was initially identiﬁ  ed on the 
electric lobe of Torpedo californica for reacting to 
antiserum against puriﬁ  ed cholinergic vesicles 
(Maroteaux et al. 1988). The synucleins became 
connected to several neurodegenerative disorders 
after the initial report of a non-Aβ component of 
AD amyloid (NAC), consisting of a 35 amino acid 
polypeptide generated by cleavage of aSyn.
The PARK1 locus, which encodes for aSyn, 
became associated with Parkinson’s disease (PD), 
when a point mutation was found in an Italian 
kindred afﬂ  icted by autosomal dominant PD. The 
mutation causes a threonine for alanine substitution 
at position 53 (A53T) (Polymeropoulos et al. 
1997). This discovery was then followed by a 
report identifying aSyn in Lewy bodies (LBs), 
concentric hyaline cytoplasmic inclusion bodies. 
All LBs were shown to contain the protein aSyn 
(Spillantini et al. 1997; Irizarry et al. 1998).
Shortly thereafter, another familial form of PD 
was linked to a mutation in aSyn causing a proline 
for alanine substitution at position 30 (A30P) (Kruger 
et al. 1998). More recently, a third mutation consisting 
of a lysine for glutamate substitution at position 46 
(E46K) was discovered to be associated with familial 
PD (Zarranz et al. 2004). Additionally, duplications 
and triplications of the PARK1 locus have also been 
linked to familial PD. The dominant nature of the 
inherited mutants is thought to reﬂ  ect a gain rather 
than a loss of function in the aSyn proteins.
After the initial discovery of aSyn in LBs in PD, 
the protein was detected in cellular inclusions in 
several other neurodegenerative diseases including 
dementia with Lewy bodies (DLB), multiple system 
atrophy (MSA), and Hallervorden-Spatz syndrome, 
now called neurodegeneration with brain iron accu-
mulation type 1 (NBIA). The neurodegenerative 
diseases that share aSyn pathology as a primary fea-
ture are collectively known as synucleinopathies.
PD is one of the most common progressive, 
neurodegenerative disorders affecting about 2% of 
people over 65 years old and 4%–5% of people over 
85 (between one and one-and-a-half million 
Americans). PD is characterized by loss of dopami-
nergic neurons in the substantia nigra pars compacta 
and is accompanied by muscle rigidity, bradykinesia, 
resting tremor and postural instability.
It is now known that LBs can be seen in pig-
mented neurons of the substantia nigra in almost 
every case of PD (Jellinger, 1987). However, LBs 
have also been observed in the brains of asymptom-
atic individuals (Nussbaum and Polymeropoulos, 
1997). The intracerebral formation and spreading 
of LB pathology has been extensively studied. LBs 
and Lewy neurites appear at deﬁ  ned induction sites 
and pathology advances in a topographically pre-
dictable sequence. As PD progresses, components 
of the autonomic, limbic, and somatomotor systems 
become particularly badly damaged. During pres-
ymptomatic stages 1–2, inclusion body pathology 
is conﬁ  ned to the medulla oblongata/pontine teg-
mentum and olfactory bulb/anterior olfactory 
nucleus. In stages 3–4, the substantia nigra and other 
areas of the midbrain and forebrain become the 
focus of pathological changes. When this happens, 
individuals start to display the ﬁ  rst disease symp-
toms. In the end-stages 5–6, the process enters the 
neocortex, and the disease manifests itself in all of 
its clinical dimensions.
α-Synuclein misfolding, aggregation, 
and toxicity
The ‘amyloid hypothesis’ (developed originally 
for Alzheimer’s disease) states that the aggregation 43
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of proteins into an ordered ﬁ  brillar structure is 
causally related to aberrant protein interactions that 
culminate in neuronal dysfunction and ultimately 
neurodegeneration (Hardy and Selkoe, 2002). The 
actual nature of the toxic species is, however, pres-
ently unknown. Evidence from PD suggests the 
hallmark inclusions (LBs) may actually be a pro-
tective mechanism neurons developed to preclude 
the accumulation of the pathogenic intermediates, 
which have been proposed to be aSyn oligomers 
(Ding et al. 2002).
Aggregation of aSyn and the putative gain of 
toxic function may contribute to haploinsufﬁ  -
ciency by entrapping the wild type protein, thus 
reducing the amount of available functional aSyn. 
Recent studies in yeast suggest that once aSyn 
starts to aggregate it may recruit aSyn away from 
other sites in the cell, harmonizing the gain and 
loss of function hypotheses (Outeiro and Lindquist, 
2003). One hypothesis is that molecular crowding 
could first accelerate the formation of aSyn 
spherical protofibrils, a process that involves 
β-sheet formation and then chain-like and annular 
protoﬁ  brils (Ding et al. 2002). Other studies show 
that crowding also dramatically accelerates aSyn 
ﬁ  bril formation. In vitro studies with puriﬁ  ed aSyn 
demonstrated that protoﬁ  bril and ﬁ  bril formation 
require different critical concentrations, suggest-
ing there are ranges under which one may form 
preferentially over the other. If annular protoﬁ  brils 
do indeed exist in vivo, they could exert toxicity 
because of their binding and permeabilization of 
vesicles. These pore-like structures formed, in 
vitro, by aSyn have been visualized by electron 
microscopy (Lashuel et al. 2002b; Lashuel et al. 
2002a) and by atomic force microscopy (Ding 
et al. 2002) and they are structurally similar to a 
subset of Aβ protoﬁ  brils and other unregulated 
pore-forming toxins (Volles et al. 2001; Lashuel 
et al. 2002b; Lashuel et al. 2002a).
Recent ﬁ  ndings in cellular systems are consistent 
with the toxic protoﬁ  bril hypothesis. The accumu-
lation of preﬁ  brillar aggregates in the membrane 
fraction, prior to the appearance of aSyn inclusions, 
was associated with Golgi fragmentation and a 
reduction in cell viability (Gosavi et al. 2002). 
Lysosomes may also be disrupted by aSyn protoﬁ  -
brils in a similar fashion. If lysosomal degradation 
of aSyn is critical in aSyn turnover this could start 
a vicious toxic cycle (Stefanis et al. 2001).
In PD ﬂ  ies, the disconnection between patho-
genesis and aSyn inclusion formation adds support 
for roles of aSyn oligomers rather than ﬁ  brillar 
inclusions in toxicity and pathogenesis (Auluck 
et al. 2002).
Notwithstanding the recent ﬁ  ndings that favor 
roles for aSyn oligomers in cellular toxicity, it is 
also likely that ﬁ  brillar and/or amorphous aSyn 
aggregates also contribute to physical damage in 
neurons (Neumann et al. 2002).
Several groups described differences in the 
aggregation kinetics of three different forms of 
aSyn (WT, A53T and A30P) in vitro (Conway et al. 
1998; Conway et al. 2000; Li et al. 2002; Narhi 
et al. 1999; Ostrerova et al. 1999; Serpell et al. 
2000). Structural differences between these aSyn 
alleles have also been reported although the crys-
tal structure of the protein is unknown (Bussell and 
Eliezer, 2003). aSyn belongs to the family of 
‘natively unstructured proteins’ because it lacks 
deﬁ  ned secondary structure under physiological 
conditions. This property of aSyn, which makes it 
different than most other drug targets, is likely to 
constitute a major challenge for drug discovery 
efforts. Nevertheless, it is known to adopt α-helical 
conformation upon lipid binding or in the presence 
of detergents.
All four forms of aSyn (WT, A30P, E46K, 
A53T) have the ability to form ﬁ  brils with the 
typical properties of other amyloids. However, the 
A30P mutant seems to form ﬁ  brils slower than WT 
aSyn, whereas the A53T ﬁ  brillizes faster than WT 
(Conway et al. 2000). These ﬁ  ndings are sugges-
tive of a toxic role for small aSyn oligomers (not 
the ﬁ  bers themselves) in disease. The A30P mutant, 
unlike A53T and WT aSyn, seems to be defective 
in binding to vesicles and membranes (Jo et al. 
2002; Jensen et al. 1998). In cell culture, the con-
formation of the A30P mutant also differs from 
that of WT and A53T aSyn (McLean et al. 2001). 
These differences also point at disease mechanisms 
that might differ depending on the mutant form of 
aSyn. The corollary to this is that distinct interven-
tion strategies might be necessary depending on 
the mutation present.
Protein misfolding, cellular quality 
control systems as targets for 
therapeutic intervention in 
neurodegenerative diseases
Protein aggregates characteristic of AD, PD, prion 
diseases, and other neurodegenerative diseases 
share common morphological and biochemical 44
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features. In addition, they co-localize with several 
of the same proteins, including ubiquitin, 
proteasome, and lysosome subunits, and molecular 
chaperones, which collectively constitute the pro-
tein quality control (QC) systems in the cell 
(Muchowski and Wacker, 2005). This sequestration 
of the cell’s QC machinery with inclusions might 
lead to a loss of function, rendering the cell less 
likely to refold/degrade other misfolded/aggre-
gated proteins, causing a series of events that may 
ultimately result in cell death.
An alternative possibility is that, with aging, 
environmental insults, mutations or other uniden-
tiﬁ  ed triggers, the activity of the QC systems 
becomes compromised causing aggregation prone 
proteins to misfold and be left “unattended”, lead-
ing to their accumulation and the consequent 
pleiotropic effects, including cell death.
A firm proof on involvement QC system in 
neurodegeneration came from genetics of familial 
PD cases (Hardy et al. 2006; Ross and Pickart, 2004; 
Dawson, 2006; Ardley and Robinson, 2004). 
Causative mutations have been identiﬁ  ed in Parkin 
and UCH-L1 genes, encoding a ubiquitin E3 ligase 
and a ubiquitin hydrolase, respectively. Recessive 
and dominant traits of inheritance for these genes 
have been determined for familial cases of PD, 
caused by mutation in Parkin and in UCH-L1. 
Homozygous mutations in the DJ-1 gene product 
have been described recently in two families with 
autosomal recessive PD inheritance. DJ-1 is likely 
a redox-sensitive molecular chaperone, activated in 
an oxidative cytoplasmic environment. Mutations in 
DJ-1 are responsible for altering the cellular response 
to oxidative stress and proteasome (Shendelman 
et al. 2004). There are some evidences suggesting 
that genetic defects in gene products associated with 
degradation pathways cause abnormal aSyn turn-
over and subsequent formation of oligomers.
Thus, identifying and targeting the misfolded state 
of each of the proteins involved in these disorders 
holds promise to constitute a useful therapeutic 
strategy (Fig. 1). It will, therefore, be important to 
continue to develop cell models which recapitulate 
the molecular mechanisms of disease and where the 
conformation of these proteins can be readily 
assessed and manipulated. A variety of such models, 
from yeast to primary dopaminergic neurons are 
already proving to be very valuable “living test 
tubes” for these types of studies due to their great 
ease of manipulation (Outeiro and Muchowski, 2004; 
Outeiro and Giorgini, 2006; Cooper et al. 2006).
Targeting neurotoxic oligomers
The stabilization of the native structure of proteins, 
preventing their initial misfolding, is an appealing 
intervention strategy. For oligomeric proteins, such 
as transthyretin, for example, compounds capable 
of stabilizing the functional tetrameric structure 
hold great potential and are in the process of being 
developed. This approach would prevent the for-
mation of the toxic intermediates and aggregated 
species and would therefore be beneﬁ  cial.
Recent experimental evidence suggests the 
formation of neurotoxic oligomers is a key patho-
logical event not only in PD but also in other 
synucleinopathies. Aggregation of misfolded pro-
teins appears to be a complex physical-chemical 
process, superimposed in the cellular environment 
and modulated by various cellular components. 
The process of protein aggregation consists of two 
major phases: a rate-limiting nucleation phase 
and the subsequent rapid polymerization phase. 
During ﬁ  brilization, soluble and aggregated species 
exist in equilibrium, which becomes greatly shifted 
towards the latter. Soluble oligomers may be 
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Figure 1. Modulation of aSyn aggregation pathway with small mol-
ecules is aimed at reducing the levels of oligomeric species. The two 
possible models of aggregation described, where oligomeric species 
are A) true aggregation intermediates, B) bypass products. In both 
models, aggregation enhancers minimize oligomer concentration by 
shifting the equilibrium towards the formation of aggregates. Dimer-
ization inhibitors prevent the subsequent steps on the aggregation 
pathway, including oligomerization. Irrespectively from the model, 
aggregation inhibitors may cause an increase in the concentration 
of oligomers either A) directly, or B) indirectly, by shifting the 
equilibrium towards the formation of protoﬁ  brils. Aggregates are 
clearly not reliable phenotypic markers to identify agents preventing 
oligomerization in cell-based screens.45
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fruitful aggregation intermediates which, by 
operational deﬁ  nition, have increased afﬁ  nity for 
ﬁ  brils. One possibility is that the process of joining 
the aggregate diminishes the neurotoxic function(s) 
of oligomers. Alternatively, oligomers could con-
stitute bypass products of aggregation, and then 
exist in equilibrium between monomers and ﬁ  brils 
(Fig. 1). The equilibrium between soluble and 
aggregated species can be shifted towards the 
former or the latter by using small molecule 
inhibitors or enhancers of aggregation, respec-
tively. Both these models suggest that enhancers 
of aggregation promote formation of large inclu-
sions, limiting the presence of all soluble species, 
including oligomers. The strategy of using aggre-
gation inhibitors, however, aiming to increase the 
levels of soluble monomers which can be readily 
subjected to degradation by proteasomes and/or 
authophagy, may not be advantageous for diseases 
where the QC system is impaired. Thus, promoting 
the formation of large inclusions appears as a safer 
and, potentially, more beneficial strategy for 
synucleinopathies and other protein aggregation 
disorders. Therefore, it is important to consider 
possible molecular targets modulating the process 
of inclusion formation, such as enzymes respon-
sible for post-translational protein modiﬁ  cation, 
proteins implicated in aggresome formation such 
as HSP70 and HDAC6, a sub-set of chaperones 
responsible for protein re-folding (HSP70, HSP27, 
HSP90), and proteins mediating the seeding and 
transport of misfolded proteins to the nucleation 
sites (Iwata et al. 2005; Bandhyopadhyay and 
Cuervo, 2007). In addition, enzymes modifying 
cytoskeleton and microtubule components and the 
afﬁ  nity of cellular protein complexes to monomers, 
oligomers, and aggregates, may also be found to 
be important regulators of inclusion body forma-
tion (Niewiadomska et al. 2006; Dimakopoulos, 
2005; Lee et al. 2006; Feng, 2006).
Drug discovery strategies
The rationale for targeting components of the QC 
systems is based on solid evidence from genetics 
and pathophysiology. While extensive studies sup-
port a major role of molecular chaperones in 
synucleinopathies as well as in other neurodegen-
erative diseases, neither these QC components nor 
those which gene products are defective in famil-
ial PD are easy drug targets for small molecules. 
Individual molecular chaperones play multiple 
roles in the cell and work in a ﬁ  nely orchestrated 
fashion to execute different cellular responses 
(Macario and Conway de Macario, 2005).
Thus, rationalizing and prioritizing selection of 
chaperones as targets is not a trivial approach. 
Notwithstanding, in vitro assays have been 
designed to identify small molecule modulators of 
chaperone activities. These assays are based on the 
re-folding of heat-inactivated luciferase in the 
absence or presence of candidate chaperones. A 
simple luminescence readout detecting the recov-
ery of the native conformation by luciferase, allows 
screening the large compound libraries in a high 
throughput manner.
The drug discovery process for synucleinopa-
thies has been delayed over the years by the elusive 
nature of the mechanisms leading to neurodegen-
eration and, subsequently, by the lack of useful 
molecular drug-targets. As a major effort to over-
come these difﬁ  culties several “black box” assays 
have been developed. These are usually cell-based 
assays which try to recapitulate phenotypic and 
functional aspects of disease. This alternative unbi-
ased approach, which does not require any assump-
tions in terms of the molecular targets and 
mechanisms involved, led, through chemical and 
genetic screens, to the identiﬁ  cation of both small 
molecules and also potentially novel drug-targets.
While “black box” assays were successful to 
identify speciﬁ  c hits in chemical screens, hit-
optimization for potency, selectivity and ADMET 
based on primary “black box assays”, has not been 
as straightforward as initially thought. Therefore, 
it is essential to identify the molecular targets of 
the identiﬁ  ed compounds in order to expedite 
development pre-clinical candidates.
Assay development
Several cell-based assays targeting key molecular 
aspects of disease, such as aSyn cytotoxicity, 
aggregation, or proteasome have been developed. 
For example, overexpression of wild type aSyn in 
mammalian cells of neuronal origin causes sig-
niﬁ  cant cytotoxicity and aggregation of misfolded 
protein. The design of this model was to mimic the 
genetic multiplication of aSyn alleles as seen in 
familial PD cases (Singleton et al. 2003), resulting 
in a 2–4 fold-increase in the levels of aSyn. This 
cell-based model has been employed for the 
validation of compounds rescuing cytotoxicity by 
inhibiting or promoting inclusion formation 46
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(Bodner et al. 2006). Subsequent assay develop-
ment was focused on early event in formation of 
oligomers, such as aSyn dimerization and oligo-
merization (Klucken et al. 2006). These next gen-
eration assays were FRET-based or employed 
readouts which allow the detection of protein-pro-
tein interactions in the cell.
Screening Platforms
Yeast cells
The budding yeast Saccharomyces cerevisiae is a 
powerful system in which to perform extensive 
genetic manipulations. Most cellular pathways are 
highly conserved from this simple eukaryote up to 
humans. Therefore, it was logical to develop yeast 
models of neurodegeneration in the hope to identify 
novel drug targets (Outeiro and Muchowski, 2004; 
Outeiro and Giorgini, 2006). In one such yeast 
model, expression of aSyn led inclusion formation 
and cytotoxicity. Importantly, cytotoxicity was 
developed by the simple duplication of the aSyn 
gene dosage, similarly to familial PD cases 
(Singleton et al. 2003; Outeiro and Lindquist, 
2003). This yeast aSyn model was employed to 
screen for genetic suppressors or enhancers of 
toxicity (Willingham et al. 2003; Cooper et al. 
2006). In a subsequent genetic screens heat shock 
proteins were identiﬁ  ed as modulators of aSyn 
aggregation, and their roles in Lewy body forma-
tion were further validated in follow-up studies in 
mammalian cells (Outeiro et al. 2006; McLean 
et al. 2004; McLean et al. 2002).
These yeast models have also been used in high 
throughput compound screens as well. While yeast 
cells are known for poor compound uptake and for 
effective drug efﬂ  ux systems that pump compounds 
out of the cell, mutations in the ERG6 and PDR1, 
3, and 5 genes, signiﬁ  cantly improve the penetration 
and availability of small molecules. Compound 
screens have led to the successful identiﬁ  cation of 
inhibitors of aSyn toxicity and aggregation, which 
might prove to have therapeutic application in the 
future (Grifﬁ  oen et al. 2006).
Mammalian cells
Phenotypic and functional PD assays were also 
developed using mammalian cells. The revolution 
in the ﬁ  eld of RNA interferences greatly enhanced 
our ability to identify novel drug targets using 
screening platforms based on mammalian cells. 
For the transient gene knock-down in mammalian 
cells RNA duplexes (siRNA) or DNA, encoding 
RNA targeting duplexes, can be used. Viral-based 
delivery metho ds for the latter approach is broadly 
used, enabling a high percentage of infection of 
cells in culture (90%), and hence to obtain uni-
form response (Berns et al. 2004; Raoul et al. 2006; 
Moffat et al. 2006). These methods can also be 
used to generate stable cell lines where the genes 
of interest are knocked down.
There is, however, a down-side to this potentially 
powerful approach. Cellular proteins are part of 
various complexes, involved in multiple cellular 
functions. Therefore, the downregulation of protein 
expression at the mRNA level will affect the activ-
ities of an indeﬁ  nite number of protein complexes 
of which the individual target-protein is part of, with 
unpredictable consequences. Such putative pleio-
tropic effects on protein levels through single mRNA 
interference can lead to discrepancies between 
genetic and small molecule screening data.
High throughput platforms, based on pheno-
typic and functional readouts in mammalian cells, 
are widely used in drug screening of both synthetic 
compound and natural product libraries. A recent 
trend has been towards high content screening 
(HCS), when various features of cell morphology 
and functions are subjected to analysis. Such 
analysis potentially provides valuable evaluation 
for the effects of the drugs in the cell. However, 
due to extremely large number of data points gen-
erated in the HTS, the sizes of the screening librar-
ies are quite limited at this point.
Nevertheless, advanced screening technologies 
provide opportunities for dissecting the cellular 
pathways involved in neurodegeneration and 
developing neuroprotective agents.
Secondary and tertiary conﬁ  rmatory assays
In the absence of a universal PD model that can 
recapitulate all features of pathology it appears 
difﬁ  cult to properly evaluate the therapeutic poten-
tial of drug-candidates using a single model sys-
tem. It is essential to validate and examine the 
properties of hits arising from primary screen in 
multiple secondary assays. Secondary assays are 
often low throughput and tedious, and are designed 
to test candidate molecules under physiological 
conditions. In PD, primary rat mesencephalic 
neuronal cultures, expressing virally delivered 
mutant (A53T) aSyn, are an example of a relevant 47
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secondary assay to validate hits modulating 
toxicity, aggregation and oligomerization of aSyn 
(Lo Bianco et al. 2002).
Fruit ﬂ  y and worm models of aSyn toxicity have 
also been developed over the years (Lo Bianco 
et al. 2002; Lakso et al. 2003; Auluck and Bonini, 
2002; Feany, 2000). Despite apparent evolutionary 
differences between mammals and invertebrates, 
these animal models accurately recapitulated cer-
tain pathological features of neurodegeneration in 
PD. Therefore invertebrate animal models became 
an important intermediate step in the validation 
and assessment of therapeutic candidates, provid-
ing qualitative conﬁ  rmation of agent efﬁ  cacies for 
PD in the context of a whole animal (Fig. 2).
Rodent PD models
The ultimate test in the development of pre-clinical 
candidates is the demonstration of their efﬁ  cacy in 
rodent disease models (Fig. 2). The development 
of accurate rodent PD models has faced several 
difﬁ  culties, due to inconsistencies in phenotypes 
and only partial recapitulation of disease features. 
Nonetheless, several PD models in mice and rats 
have been developed and used in the recent years 
for investigating the molecular pathogenesis 
involved in the disease (Masliah et al. 2000; Lo 
Bianco et al. 2002; St Martin et al. 2007).
Multiple transgenic mouse models of PD over-
expressing wild-type and mutant forms of aSyn 
have been generated to help elucidate the role of 
the protein in the disease. Although none of the 
lines created display significant dopaminergic 
neuronal death in the substantia nigra, the models 
have speciﬁ  c attributes that recapitulate some fea-
tures of synucleinopathies and are useful to study 
the potential pathogenic role of aSyn. In terms of 
widespread and robust aSyn aggregation, one of 
the best characterized lines is the line D aSyn over-
expressers reported by Masliah et al. These mice 
develop an age-dependent aSyn aggregation within 
numerous neurons in the cortex and in the substan-
tia nigra, as well as a detectable loss of striatal 
dopaminergic terminals.
To address the need for an animal model with 
speciﬁ  c nigrostriatal degeneration, researchers have 
employed gene therapy techniques. Viral vectors, 
including adeno-associated virus and lentivirus, 
have been successfully used to generate mouse, rat 
and nonhuman primate models with nigrostriatal 
degeneration by targeting aSyn expression to the 
substantia nigra. Along with recapitulating the car-
dinal pathological features of PD, these viral-based 
models provide a slow disease progression that more 
closely mimics human disease and allows for earlier 
points of characterization and/or intervention.
These rodent models provide novel opportuni-
ties to expedite drug development for therapeutic 
intervention in PD and other synucleinopathies.
Conclusions
The primary pathological role proposed for aSyn 
oligomeric species in neurodegeneration is consis-
tent with the growing number of experimental 
evidence. Although the molecular basis for oligo-
mer neurotoxicity is still elusive, oligomeric spe-
cies likely have a negative impact on the ubiquitin 
proteasome degradation machinery, and on mito-
chondrial function. These species also seem to 
trigger cellular defense pathways, such as the 
stress-response and caspase activation. The kinet-
ics of oligomer formation is likely modulated by 
Invertebrate animal models
Cell-based screening assay
Transgenic mouse models
hits validated hits early therapeutic leads
Primary screens Secondary/confirmatory assays
Clinic
medicinal chemistry
Figure 2. Drug discovery array describing the compound progression sequence from cell-based (black-box) assays through secondary, 
disease-speciﬁ  c, validation tests in other models organisms and, ultimately to the clinic.48
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various cellular components, aging, and external 
stimuli, including oxidation. The identiﬁ  cation of 
modiﬁ  ers, capable of reducing oligomerization, is 
envisioned as a ﬁ  rst priority for genetic screens. 
The oligomerization process can also be amenable 
to modulation by small molecules which are begin-
ning to emerge in drug screens based on phenotypic 
and functional cell assays. Due to insufﬁ  cient 
knowledge on the molecular targets modulating 
oligomerization, the evaluation of the therapeutic 
potential of the compounds identiﬁ  ed in cell-based 
screens, may be tedious and not straightforward. 
A prudent experimental approach will be to assess 
their therapeutic values in genetic animal models. 
This concerted approach will ensure that the most 
promising leads can be moved forward towards 
human drug development irrespectively from their 
molecular mechanism of action.
Acknowledgements
TFO is supported by Fundação Calouste Gulbenkian 
and a grant from the Michael J. Fox Foundation.
References
Ardley, H.C. and Robinson, P.A. 2004. Neurodegener Dis., 1:71–87.
Auluck, P.K. and Bonini, N.M. 2002. Nat. Med., 8:1185–6.
Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M. and Bonini, N.M. 
2002. Science, 295:865–8.
Bandhyopadhyay, U. and Cuervo, A.M. 2007. Exp. Gerontol., 42:120–8.
Berns, K., Hijmans, E.M., Mullenders, J., Brummelkamp, T.R., Velds, A., 
Heimerikx, M., Kerkhoven, R.M., Madiredjo, M., Nijkamp, W., 
Weigelt, B., Agami, R., Ge, W., Cavet, G., Linsley, P.S., Beijersbergen, 
R.L. and Bernards, R. 2004. Nature, 428:431–7.
Bisaglia, M., Tessari, I., Pinato, L., Bellanda, M., Giraudo, S., Fasano, M., 
Bergantino, E., Bubacco, L. and Mammi, S. 2005. Biochemistry, 
44:329–39.
Bodner, R.A., Outeiro, T.F., Altmann, S., Maxwell, M.M., Cho, S.H., 
Hyman, B.T., McLean, P.J., Young, A.B., Housman, D.E. and 
Kazantsev, A.G. 2006. Proc. Natl. Acad. Sci., U.S.A., 103:4246–51.
Braak, H., Braak, E., Yilmazer, D., de Vos, R.A., Jansen, E.N. and Bohl, J. 
1996. J. Neural Transm., 103:455–90.
Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-
Keil, D. and Rub, U. 2002. J. Neurol., 249(Suppl 3):III/1–5.
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. and Del Tredici, K. 
2004. Cell. Tissue Res., 318:121–34.
Broersen, K., van den Brink, D., Fraser, G., Goedert, M. and Davletov, B. 
2006. Biochemistry, 45:15610–6.
Bussell, R., Jr. and Eliezer, D. 2003. J. Mol. Biol., 329:763–78.
Caughey, B. and Lansbury, P.T. 2003. Annu. Rev. Neurosci., 26:267–98.
Cheng, Y., LeGall, T., Oldﬁ  eld, C.J., Mueller, J.P., Van, Y.Y., Romero, P., 
Cortese, M.S., Uversky, V.N. and Dunker, A.K. 2006. Trends Bio-
technol., 24:435–42.
Conway, K.A., Harper, J.D. and Lansbury, P.T. 1998. Nat. Med., 4:1318–20.
Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E. and 
Lansbury, P.T., Jr. 2000. Proc. Natl. Acad. Sci., U.S.A., 97:571–6.
Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., 
Liu, K., Xu, K., Strathearn, K.E., Liu, F., Cao, S., Caldwell, K.A., 
Caldwell, G.A., Marsischky, G., Kolodner, R.D., Labaer, J., Rochet, J.C., 
Bonini, N.M. and Lindquist, S. 2006. Science.
Dawson, T.M. 2006. J. Neural. Transm. Suppl., 209–13.
Dimakopoulos, A.C. 2005. Curr. Alzheimer Res., 2:19–28.
Ding, T.T., Lee, S.J., Rochet, J.C. and Lansbury, P.T., Jr. 2002. Biochemis-
try, 41:10209–17.
Feany, M.B. 2000. J. Neuropathol. Exp. Neurol., 59:847–56.
Feng, J. 2006. Neuroscientist, 12:469–76.
Fernagut, P.O. and Chesselet, M.F. 2004. Neurobiol. Dis., 17:123–30.
Fink, A.L. 2006. Acc. Chem. Res., 39:628–34.
Gomez-Isla, T., Irizarry, M.C., Mariash, A., Cheung, B., Soto, O., Schrump, S., 
Sondel, J., Kotilinek, L., Day, J., Schwarzschild, M.A., Cha, J.H., 
Newell, K., Miller, D.W., Ueda, K., Young, A.B., Hyman, B.T. and 
Ashe, K.H. 2003. Neurobiol. Aging, 24:245–58.
Gosavi, N., Lee, H.J., Lee, J.S., Patel, S. and Lee, S.J. 2002. J. Biol. Chem., 
277:48984–92.
Greenbaum, E.A., Graves, C.L., Mishizen-Eberz, A.J., Lupoli, M.A., 
Lynch, D.R., Englander, S.W., Axelsen, P.H. and Giasson, B.I. 2005. 
J. Biol. Chem., 280:7800–7.
Grifﬁ  oen, G., Duhamel, H., Van Damme, N., Pellens, K., Zabrocki, P., 
Pannecouque, C., van Leuven, F., Winderickx, J. and Wera, S. 2006. 
Biochim. Biophys. Acta., 1762:312–8.
Hardy, J., Cai, H., Cookson, M.R., Gwinn-Hardy, K. and Singleton, A. 2006. 
Ann. Neurol., 60:389–98.
Hardy, J. and Selkoe, D.J. 2002. Science, 297:353–6.
Irizarry, M.C., Growdon, W., Gomez-Isla, T., Newell, K., George, J.M., 
Clayton, D.F. and Hyman, B.T. 1998. J. Neuropathol. Exp. Neurol., 
57:334–7.
Iwata, A., Christianson, J.C., Bucci, M., Ellerby, L.M., Nukina, N., 
Forno, L.S. and Kopito, R.R. 2005. Proc. Natl. Acad. Sci., U.S.A., 
102:13135–40.
Jellinger, K. 1987. Adv. Neurol., 45:1–18.
Jensen, P.H., Nielsen, M.S., Jakes, R., Dotti, C.G. and Goedert, M. 1998. 
J. Biol. Chem., 273:26292–4.
Jo, E., Fuller, N., Rand, R.P., St George-Hyslop, P. and Fraser, P.E. 2002. 
J. Mol. Biol., 315:799–807.
Kahle, P.J., Neumann, M., Ozmen, L. and Haass, C. 2000. Ann. N. Y. Acad. 
Sci., 920:33–41.
Kirik, D., Annett, L.E., Burger, C., Muzyczka, N., Mandel, R.J. and 
Bjorklund, A. 2003. Proc. Natl. Acad. Sci., U.S.A., 100:2884–9.
Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T.E., 
Muzyczka, N., Mandel, R.J. and Bjorklund, A. 2002. J. Neurosci, 
22:2780–91.
Klein, R.L., King, M.A., Hamby, M.E. and Meyer, E.M. 2002. Hum. Gene 
Ther., 13:605–12.
Klucken, J., Outeiro, T.F., Nguyen, P., McLean, P.J. and Hyman, B.T. 2006. 
Faseb. J., 20:2050–7.
Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., 
Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. 1998.  Nat. Genet., 
18:106–8.
Lakso, M., Vartiainen, S., Moilanen, A.M., Sirvio, J., Thomas, J.H., Nass, R., 
Blakely, R.D. and Wong, G. 2003. J. Neurochem., 86:165–72.
Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T. and Lansbury, P.T., Jr. 
2002a. Nature, 418:291.
Lashuel, H.A., Petre, B.M., Wall, J., Simon, M., Nowak, R.J., Walz, T. and 
Lansbury, P.T., Jr. 2002b. J. Mol. Biol., 322:1089–102.
Lee, H.J., Khoshaghideh, F., Lee, S. and Lee, S.J. 2006. Eur. J. Neurosci., 
24:3153–62.
Li, J., Uversky, V.N. and Fink, A.L. 2002. Neurotoxicology, 23:553–67.
Lo Bianco, C., Ridet, J.L., Schneider, B.L., Deglon, N. and Aebischer, P. 
2002. Proc. Natl. Acad. Sci., U.S.A., 99:10813–8.
Macario, A.J. and Conway de Macario, E. 2005. N. Engl. J. Med., 
353:1489–501.
Maroteaux, L., Campanelli, J.T. and Scheller, R.H. 1988. J. Neurosci., 
8:2804–15.
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., 
Takeda, A., Sagara, Y., Sisk, A. and Mucke, L. 2000. Science, 
287:1265–9.
Matyus, L. 1992. J. Photochem. Photobiol. B., 12:323–37.49
Targeting aSyn oligomerization in Synucleinopathies
Perspectives in Medicinal Chemistry 2008:2 
Matyus, L., Szollosi, J. and Jenei, A. 2006. J. Photochem. Photobiol. B., 
83:223–36.
McLean, P.J., Kawamata, H. and Hyman, B.T. 2001. Neuroscience, 
104:901–12.
McLean, P.J., Kawamata, H., Shariff, S., Hewett, J., Sharma, N., Ueda, K., 
Breakeﬁ  eld, X.O. and Hyman, B.T. 2002. J. Neurochem., 83:846–54.
McLean, P.J., Klucken, J., Shin, Y. and Hyman, B.T. 2004. Biochem. Biophys. 
Res. Commun., 321:665–9.
Moffat, J., Grueneberg, D.A., Yang, X., Kim, S.Y., Kloepfer, A.M., 
Hinkle, G., Piqani, B., Eisenhaure, T.M., Luo, B., Grenier, J.K., 
Carpenter, A.E., Foo, S.Y., Stewart, S.A., Stockwell, B.R., 
Hacohen, N., Hahn, W.C., Lander, E.S., Sabatini, D.M. and Root, D.E. 
2006. Cell., 124:1283–98.
Muchowski, P.J. 2002. Neuron, 35:9–12.
Muchowski, P.J. and Wacker, J.L. 2005. Nat. Rev. Neurosci., 6:11–22.
Munishkina, L.A. and Fink, A.L. 2007. Biochim. Biophys. Acta., 
1768:1862–85.
Narhi, L., Wood, S.J., Steavenson, S., Jiang, Y., Wu, G.M., Anaﬁ  , D., 
Kaufman, S.A., Martin, F., Sitney, K., Denis, P., Louis, J.C., 
Wypych, J., Biere, A.L. and Citron, M. 1999. J. Biol. Chem., 
274:9843–6.
Neumann, M., Kahle, P.J., Giasson, B.I., Ozmen, L., Borroni, E., 
Spooren, W., Muller, V., Odoy, S., Fujiwara, H., Hasegawa, M., 
Iwatsubo, T., Trojanowski, J.Q., Kretzschmar, H.A. and Haass, C. 
2002. J. Clin. Invest., 110:1429–39.
Niewiadomska, G., Baksalerska-Pazera, M. and Riedel, G. 2006. Rev. 
Neurosci., 17:581–618.
Nussbaum, R.L. and Polymeropoulos, M.H. 1997. Hum. Mol. Genet., 
6:1687–91.
Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J. and 
Wolozin, B. 1999. J. Neurosci., 19:5782–91.
Outeiro, T.F. and Giorgini, F. 2006. Biotechnol. J., 1:258–69.
Outeiro, T.F., Klucken, J., Strathearn, K.E., Liu, F., Nguyen, P., Rochet, J.C., 
Hyman, B.T. and McLean, P.J. 2006. Biochem. Biophys. Res. 
Commun., 351:631–8.
Outeiro, T.F. and Lindquist, S. 2003. Science, 302:1772–5.
Outeiro, T.F. and Muchowski, P.J. 2004. J. Mol. Neurosci., 23:49–60.
Perrin, R.J., Woods, W.S., Clayton, D.F. and George, J.M. 2000. J. Biol. 
Chem., 275:34393–8.
Petrassi, H.M., Johnson, S.M., Purkey, H.E., Chiang, K.P., Walkup, T., 
Jiang, X ., Powers, E.T. and Kelly, J.W. 2005. J. Am. Chem. Soc., 
127:6662–71.
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., 
Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., 
Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., 
Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., 
Golbe, L.I. and Nussbaum, R.L. 1997. Science, 276:2045–7.
Raoul, C., Barker, S.D. and Aebischer, P. 2006. Gene Ther., 13:487–95.
Ross, C.A. and Pickart, C.M. 2004. Trends Cell. Biol., 14:703–11.
Ross, C.A. and Poirier, M.A. 2004. Nat. Med., 10(Suppl):S10–7.
Serpell, L.C., Berriman, J., Jakes, R., Goedert, M. and Crowther, R.A. 2000. 
Proc. Natl. Acad. Sci., U.S.A., 97:4897–902.
Shendelman, S., Jonason, A., Martinat, C., Leete, T. and Abeliovich, A. 
2004. PLoS Biol., 2:e362.
Shtilerman, M.D., Ding, T.T. and Lansbury, P.T., Jr. 2002. Biochemistry, 
41:3855–60.
Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., 
Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., 
Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., 
Cookson, M.R., Muenter, M., Baptista, M., Miller, D., Blancato, J., 
Hardy, J. and Gwinn-Hardy, K. 2003. Science, 302:841.
Soto, C., Estrada, L. and Castilla, J. 2006. Trends Biochem. Sci., 31:150–5.
Spillantini, M.G. and Goedert, M. 2000. Ann. N. Y. Acad. Sci., 920:16–27.
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. 
and Goedert, M. 1997. Nature, 388:839–40.
St Martin, J.L., Klucken, J., Outeiro, T.F., Nguyen, P., Keller-McGandy, C., 
Cantuti-Castelvetri, I., Grammatopoulos, T.N., Standaert, D.G., 
Hyman, B.T. and McLean, P.J. 2007. J. Neurochem., 100:1449–57.
Stefanis, L., Larsen, K.E., Rideout, H.J., Sulzer, D. and Greene, L.A. 2001. 
J. Neurosci., 21:9549–60.
Thomas, P.J., Qu, B.H. and Pedersen, P.L. 1995. Trends Biochem. Sci., 
20:456–9.
Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., 
Otero, D.A., Kondo, J., Ihara, Y. and Saitoh, T. 1993. Proc. Natl. 
Acad. Sci., U.S.A., 90:11282–6.
Uversky, V.N., E, M.C., Bower, K.S., Li, J. and Fink, A.L. 2002. FEBS Lett., 
515:99–103.
van der Putten, H., Wiederhold, K.H., Probst, A., Barbieri, S., Mistl, C., 
Danner, S., Kauffmann, S., Hofele, K., Spooren, W.P., Ruegg, M.A., 
Lin, S., Caroni, P., Sommer, B., Tolnay, M. and Bilbe, G. 2000. 
J. Neurosci., 20:6021–9.
Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., 
Kessler, J.C. and Lansbury, P.T., Jr. 2001. Biochemistry, 40:7812–9.
Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A. and Lansbury, P.T., Jr. 
1996. Biochemistry, 35:13709–15.
Willingham, S., Outeiro, T.F., DeVit, M.J., Lindquist, S.L. and 
Muchowski, P.J. 2003. Science, 302:1769–72.
Wiseman, R.L., Green, N.S. and Kelly, J.W. 2005. Biochemistry, 44:9265–74.
Yamada, M., Iwatsubo, T., Mizuno, Y. and Mochizuki, H. 2004. J. Neuro-
chem., 91:451–61.
Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., 
Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., 
Llorens, V., Tortosa, E.G., Del Ser, T., Munoz, D.G. and De 
Yebenes, J.G. 2004. Ann. Neurol., 55:164–73.
Zibaee, S., Jakes, R., Fraser, G., Serpell, L.C., Crowther, R.A. and Goedert, 
M. 2007. J. Mol. Biol., 374:454–64.